French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62(8):1252-1260.Search in Google Scholar
Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094-1120.Search in Google Scholar
Milovanovic JR, Jankovic SM. Population pharmacokinetic of antiepileptic drugs in different populations. CEJM. 2013;8(4):383-391.Search in Google Scholar
Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9(2):199-216.Search in Google Scholar
Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695-714.Search in Google Scholar
Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707-724.Search in Google Scholar
Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther. 2008;14(2):120-142.Search in Google Scholar
Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother. 2007;7(2):179-193.Search in Google Scholar
Ben Mahmoud L, Hakim A, Ghozzi H, et al. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy. Rev Neurol (Paris). 2017;173(3):159-163.Search in Google Scholar
Correa T, Rodriguez I, Romano S. Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos. 2008;29(9):511-520.Search in Google Scholar
Jankovic SM, Milovanovic JR, Jankovic S. Factors influencing valproate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther. 2010;48(11):767-775.Search in Google Scholar
Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat. 2007;3(1):117-131.Search in Google Scholar
Aghebati T, Foroughipour M, Azarpazhooh MR, et al. Relationship between Patient Demographic Characteristics, Valproic Acid Dosage and Clearance in Adult Iranian Patients. Iran J Basic Med Sci. 2012;15(2):702-708.Search in Google Scholar
Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84(5):816-834.Search in Google Scholar
Kho ME, Duffett M, Willison DJ, et al. Written informed consent and selection bias in observational studies using medical records: systematic review. BMJ. 2009;338:b866.Search in Google Scholar
Traynard P, Ayral G, Twarogowska M, et al. Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil. CPT Pharmacometrics Syst Pharmacol. 2020;9(4):198-210.Search in Google Scholar
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.Search in Google Scholar
Sherwin CM, Kiang TK, Spigarelli MG, et al. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51(9):573-590.Search in Google Scholar
Han K, Bies R, Johnson H, et al. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. Clin Pharmacokinet. 2011;50(3):201-214.Search in Google Scholar
Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276.Search in Google Scholar
Greenberg RG, Melloni C, Wu H, et al. Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach. Clin Neuropharmacol. 2016;39(5):232-240.Search in Google Scholar
Sanchez-Alcaraz A, Quintana MB, Lopez E, et al. Valproic acid clearance in children with epilepsy. J Clin Pharm Ther. 1998;23(1):31-34.Search in Google Scholar
Serrano BB, Garcia Sanchez MJ, Otero MJ, et al. Valproate population pharmacokinetics in children. J Clin Pharm Ther. 1999;24(1):73-80.Search in Google Scholar
Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45(4):351-363.Search in Google Scholar
Jiang DC, Wang L, Wang YQ, et al. Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin. 2007;28(10):1677-1684.Search in Google Scholar
Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236-241.Search in Google Scholar
Yukawa E, Honda T, Ohdo S, et al. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. J Pharm Pharmacol. 1997;49(8):751-756.Search in Google Scholar
Battino D, Croci D, Granata T, et al. Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine. Ther Drug Monit. 1992;14(5):376-379.Search in Google Scholar
